Stereotactic ablative radiotherapy (SABR) is a modern, more precise delivery technique of radiotherapy, which delivers high doses of radiation while causing less damage to surrounding healthy tissue than conventional radiotherapy.
It is now used as part of NHS England's latest national evaluation program. NHS England has invested £15m over three years to assess the use of SABR through its Commissioning through Evaluation initiative.
Evidence shows that SABR can be effective when used to treat non-small cell lung cancer however; there is less clinical evidence to show that SABR is effective for other cancers.
NHS England's Commissioning through Evaluation program will increase the number of cancers being treated to include oligometastatic disease (cancer that has spread to another part of the body), primary liver tumors and the re-irradiation of cancers in the pelvis and spine.
Sean Duffy, National Clinical Director for Cancer at NHS England, said, "This program will allow us to assess this promising type of radiotherapy while enabling people who may benefit to access it as close to home as possible."